Favrille Announces Initiation of Phase II Clinical Trial in Europe

Favrille has announced that the first patient has been enrolled in a physician-sponsored Phase II clinical trial evaluating the company's lead product candidate, FavId.

The European-only trial is being conducted by Franco Cavalli and is open to patients with all subtypes of indolent B-cell non-Hodgkin's lymphoma.

Both treatment-naive patients and patients who are relapsed or refractory to prior treatments for their disease are eligible for the trial.